Abstract
Bevacizumab treatment is associated with an increased risk of hypertension (HTN), a potential marker for effectiveness. We aimed to assess whether grades 2–3 HTN during bevacizumab treatment was associated with increased overall survival (OS) or progression-free survival (PFS). One hundred and eighty-one patients with metastatic colorectal cancer (CRC), who were treated in our Department from January 2009–February 2011 were included. Bevacizumab was administered jointly with standard first- or second-line chemotherapy protocols. Blood pressure was measured before each treatment. HTN was graded using common toxicity criteria. There were 181 CRC patients. Grades 2–3 HTN developed in 81 patients (44.75 %) but not in 100 patients (55.25 %); no patient developed grades 4–5 HTN. Median follow-up was 15.2 months. HTN was associated with better OS in HTN-positive versus HTN-negative patients (median not reached vs. 36.8 months, p = 0.029) and better PFS (29.9 vs. 17.2 months, p = 0.024, respectively). Bevacizumab-related HTN may represent a biomarker for clinical benefit in metastatic colorectal cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42. doi:10.1056/NEJMoa032691.
Kabbinavar F, Hurwitz HI, Fehrenbacher L, Meropol NJ, Novotny WF, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60–5. doi:10.1200/JCO.2003.10.066.
Giantonio BJ, Catalano PJ, Meropol NJ, O’Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539–44. doi:10.1200/JCO.2006.09.6305.
Ranpura V, Pulipati B, Chu D, Zhu X, Wu S. Increased risk of high-grade HTN with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens. 2010;23:460–8. doi:10.1038/ajh.2010.25.
Van Cutsem E, Rivera F, Berry S, Kretzschmar A, Michael M, DiBartolomeo M, Mazier MA, Canon JL, Georgoulias V, Peeters M, Bridgewater J, Cunningham D. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842–7. doi:10.1093/annonc/mdp233.
Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist. 2009;14:862–70. doi:10.1634/theoncologist.2009-0071.
Maitland ML, Moshier K, Imperial J, Kasza E, Karrison T, Elliot W, Undevia SD, Stadler W, Desai AA, Ratain MJ. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. Am Soc Clin Oncol ASCO; Atlanta GA, USA. J Clin Oncol. 2006;24:18S, abstr 2035.
De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S. Bevacizumab-related arterial HTN as a predictive marker in metastatic colorectal cancer patients. Cancer Chemother Pharmacol. 2011;68:1207–13. doi:10.1007/s00280-011-1604-1.
Mir O, Coriat R, Cabanes L, Ropert S, Billemont B, Alexandre J, Durand JP, Treluyer JM, Knebelmann B, Goldwasser F. An observational study of bevacizumab-induced HTN as a clinical biomarker of antitumor activity. Oncologist. 2011;16:1325–32. doi:10.1634/theoncologist.2010-0002.
Osterlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P. HTN and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy. Br J Cancer. 2011;104:599–604. doi:10.1038/bjc.2011.2.
Scartozzi M, Galizia E, Chiorrini S, Giampieri R, Berardi R, Pierantoni C, Cascinu S. Arterial HTN correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol. 2009;20:227–30. doi:10.1093/annonc/mdn637.
Hurwitz H, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O. Analysis of early HTN (HTN) and clinical outcome with bevacizumab (BV). Am Soc Clin Oncol ASCO; Chicago IL, USA. J Clin Oncol. 2010;28:15s, abstr 3039.
CTCAE. Common terminology criteria for adverse events (version 4.02). U.S. Department of Health & Human Services, National Cancer Institute NCI, National Institutes of Health NIH, Bethesda MD, USA. Available online: http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf. (2009) Accessed 16 May 2012.
Author information
Authors and Affiliations
Corresponding author
Additional information
E. Tahover and B. Uziely contributed equally to this work.
Rights and permissions
About this article
Cite this article
Tahover, E., Uziely, B., Salah, A. et al. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 30, 327 (2013). https://doi.org/10.1007/s12032-012-0327-4
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-012-0327-4